Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sealed Air Corp. (SEE), Grace (W.R.) & Co. (GRA): Iridian Asset Management Discloses 13F Portfolio for Q2

Page 1 of 2

David Cohen and Harold Levy are founders of Iridian Asset Management. Messrs. Cohen and Levy are special situation investors focusing on depressed companies that are going through significant changes. According to the latest 13F filing, Iridian Asset Management revealed an equity portfolio valued at $11.87 billion, with a total of 81 positions. Iridian Asset Management has a diversified portfolio, mainly invested in materials and technology sectors. As the filing stated, the hedge fund’s largest positions are represented by Sealed Air Corp. (NYSE:SEE), Valeant Pharmaceuticals International, Inc (NYSE:VRX), Grace (W.R.) & Co. (NYSE:GRA) and Delta Air Lines Inc. (NYSE:DAL).

Harold Levy Iridian Asset Management


We track hedge funds and prominent investors because our research has shown that a select group of their top stock picks delivered superior risk-adjusted returns. The 15 most popular small-cap stocks delivered a monthly alpha of 80 basis points, while the 50 most popular large-cap stocks among hedge funds had a monthly alpha of about 6 basis points per month between 1999 and 2012. This means investors would have generated a double-digit alpha per year simply by imitating the 15 most popular small-cap stocks among hedge funds. Moreover, we have been tracking the performance of these small-cap stocks since the end of August 2012, we obtained returns of more than 137% vs. S&P 500′s 57% gain (see the details here).

In the next sections, we will analyze Iridian Asset Management’s biggest holdings as of the end of March. On the first spot is Sealed Air Corp. (NYSE:SEE), in which the fund holds 13.38 million shares, valued at $609.61 million. Recently, Sealed Air Corp. (NYSE:SEE) reported its financial results, for the first quarter of 2015. As company’s President and CEO Jerome A. Peribere said, “Our first quarter 2015 performance was a strong start to the year despite currency headwinds.” The company posted net sales of $1.75 billion, down from $1.83 billion a year earlier. The company posted an increase in diluted earnings per share by 39.4% on the year to $0.46. Aside from Iridian Asset Management, among Sealed Air Corp. (NYSE:SEE)’s shareholders is Jean-Marie Eveillard’s First Eagle Investment Management with 4.39 million shares as of the end of March.

Valeant Pharmaceuticals International, Inc (NYSE:VRX) represents Iridian Asset Management’s second-largest position in terms of value. During the first quarter, Iridian’s stake in the pharmaceutical company was cut by 22% to 3.04 million shares valued at $604.51 million. Valeant Pharmaceuticals International, Inc (NYSE:VRX)’s latest financial results included revenue of $2.19 billion, an increase of 16.15% over the prior year, including $140 million negative influence of currency fluctuations. Moreover, its net income amounted to $74.5 million, equal to $0.21 per share. The pharmaceutical company is optimistic regarding its financial results for 2015, expecting an increase in revenue almost by 14% to $10.6 billion. Jeffrey Ubben’s ValueAct Capital held the largest stake in Valeant Pharmaceuticals International, Inc (NYSE:VRX) as of the end of 2014, but a couple of months ago, Bill Ackman’s Pershing Square disclosed a new activist stake that contains 19.47 million shares.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!